GMR
The Original

INTEGRATIVE ANALYSIS OF CORONARY ARTERY DISEASE: THE ROLE OF PHARMACOLOGICAL INTERVENTIONS, MICROBIAL PATHOGENESIS, CLINICAL MEDICINE, AND ANATOMICAL VARIATIONS IN CARDIOVASCULAR RISK MANAGEMENT

Muhammad Anwar Ul Mustafa Jamil[1], **Dr. Shramik Rawal**[2], **Dr. Hina Zehra Jafri**[3], **Nabiha Naeem**[4], **Dr. Shanza Khaliq Ali**[5], **Dr. Muhammad Ayhan Amir**[6]*, **Dr. Sudhair Abbas Bangash**[7]*, **Aaqil Arshad Hulikatti**[8]

[1] Department of General Medicine, Aziz Bhatti Shaheed Teaching Hospital, Gujrat, Pakistan.
[2] Internal Medicine, Mater Dei Hospital, Malta.
[3] Department of Anatomy, Dow Medical College, Dow University of Health Sciences (DUHS), Pakistan.
[4] Life Sciences Department, School of Science, University of Management and Technology, Lahore, Pakistan.
[5] Department of Anatomy, Dow Medical College, Dow University of Health Sciences (DUHS), Pakistan.
[6] Internal Medicine Trainee (IMT), University Hospitals Dorset NHS Foundation Trust, UK.
ORCID: 0000-0003-0726-3703
Email: MuhammadAyhan.Amir@nhs.net
[7] Faculty of Life Science, Department of Pharmacy, Sarhad University of Science and Information Technology, Peshawar, Pakistan.
Email: sudhair.fls@suit.edu.pk
[8] School of Dental Sciences, Universiti Sains Malaysia Health Campus, Kubang Kerian, Kelantan, Malaysia.
*Corresponding Authors: Dr. Muhammad Ayhan Amir & Dr. Sudhair Abbas Bangash

ABSTRACT
Many People develop coronary heart disease and mortality every year, and some of the factors that might cause it include genetic, microbiological, and lifestyle decisions. To properly treat and prevent coronary artery disease (CAD), we need to know more about its causes, its genetic, microbiological, and lifestyle interactions. 130 individuals with CAD participated in cross-sectional research spanning eighteen months with regard to demographic, clinical, pharmacological, anatomical, and microbiological data. The statistical study included multivariate and descriptive methods. Gender has no obvious correlation with CAD degree. Moreover, severe CAD was connected to both structural variations and bacterial infections including Chlamydia pneumoniae. Ultimately, as CAD is complex, every individual requires a different mix of treatments including microbial control and pharmacological interventions.

KEYWORDS: Coronary artery disease, microbial pathogenesis, anatomical variations, statin use, personalized medicine.

INTRODUCTION
Global healthcare systems and economy are greatly impacted by coronary artery disease (CAD), which continues to be a major source of morbidity and mortality [1]. Many things can go wrong with the heart that would lead to fatty plaques accumulating in the coronary veins. This accumulation narrows the lumen, therefore preventing normal blood flow and potentially causing heart attack, angina, and ischemia [2]. The problematic development of CAD depends on several elements, including environmental variables [3], genetics, lifestyle choices (including smoking, exercise, and diet), and These interactions among these elements lead the disease to manifest itself differently, which makes it difficult for professionals and physicians to recognize and treat. CAD is still a major issue in healthcare even if diagnosis and treatment technologies have advanced as it is difficult to identify and can strike anybody at any moment. Drug therapies for CAD have mostly aimed at preventing plaques from developing, maintaining thrombi from developing, and therefore enhancing vascular function [4].
Several medications, including aspirin pills, statins, angiotensin-converting enzyme inhibitors (ACEIs), and others, have been found to reduce cardiovascular events and raise life rates [5]. These drugs might not, however, affect everyone the same way. This diversity emphasizes how crucial it is to understand more about each patient's particular characteristics, including genetic variants, co-occurring diseases, and lifestyle decisions, thus customizing therapies to attain the best outcomes [6]. Microbial illness has been a crucial component in CAD's expansion in recent years. Some illnesses, like Porphyromonas gingivalis and Chlamydia pneumonia, have been associated to inflammatory mechanisms causing atherosclerosis [7]. The gut microbiome also piques curiosity among people as it might affect immunological responses, lipid metabolism, and inflammation all over the body. Though we still have a lot to learn about the relationship between microbial elements and heart health, it could provide fresh avenues for treatment and

avoidance of heart disease.

New research indicates that by lowering inflammation and enhancing lipid profiles, modifying the gut flora with probiotics or by altering your diet might help your heart health [8]. Treatment of CAD still depends much on early detection and risk screening. Two modern imaging technologies that have greatly improved diagnosis accuracy and given clinicians a greater knowledge of how the coronary arteries are created and function are intravascular ultrasonic waves (IVUS) and coronary computed tomography angiography (CCTA [9]). But uneven access to health care, particularly in areas with limited funds, makes it difficult to employ these devices generally. Furthermore difficult to apply clinical standards in daily medical practice is the fact that various patient populations and healthcare systems make it difficult to do such. Finding CAD early depends much on easily available, reasonably priced diagnostic instruments that may be utilized anywhere across the globe.

Variations in the anatomy of the coronary arteries, such as those resulting from changes in which coronary artery is dominant or non-functioning coronary arteries, have been seen to influence the course of the illness and personal outcomes. These basic issues might make treatment approaches more customized to each individual necessary, and revascularization procedures may not be as effective [10]. By means of innovative imaging technologies in pre-operative planning, we can raise intervention success rates and enable us to better grasp these variations. These fresh results highlight the need of considering factors other than the clinical and drug-based aspects of CAD treatment. The outcomes could also be affected by the structural and microbiological components.

Although a lot of research has been conducted on several areas of CAD, many issues remain regarding the interactions among the morphological, clinical, pharmacological, and microbiological components to influence the risk of heart disease. By delving further into these problems, this study seeks to close these gaps and thereby assist to create more complete and efficient strategies for CAD prevention and treatment. By considering these complex elements, this study enhances the health outcomes for individuals with coronary artery disease and facilitates the customizing of treatment strategies.

METHODOLOGY

Sample Size Calculation: Group size for the study was calculated using a 95% confidence level and a 5% margin of error. Considering the present CAD incidence rates and expected impact sizes from past studies, at least 130 individuals were considered to be enough for statistical power. Every lost or missing data point was considered throughout calculation to ensure the subgroup studies would fairly reflect themselves.

Study Design and Location: This was a cross-sectional study conducted at the Hayatabad Medical Complex, Peshawar. The study was carried out over duration of 18 months, starting from January 2024 to June 2025.

Inclusion and Exclusion Criteria: The study included persons between the ages of 30 and 70 who satisfied clinical, biochemical, and imaging criteria needed for a CAD diagnosis. Those who just underwent surgery, had significant illnesses that would affect the outcomes, or were born with heart problems were not let to participate.

Data collection: Lab tests, organized interviews, and medical record searches were all combined in data collecting efforts. The patient's medical background, pharmacological treatments, lifestyle choices, and demographics were among the many topics of research conducted on Imaging studies aimed at examining variations in structure and disease severity included coronary computed tomography angiography (CCTA). Microbial research was also conducted using samples from mouth and blood tests in search of relationships between gut flora profiles and pathogenic bacteria.

Pharmalogical assessments: The pharmacological results largely concerned the usage of statins, antiplatelet medications, and other cardiac medications. Medication adherence was gauged using pharmacy records and patient self-report. Genetic testing for variations in drug metabolism was conducted for some of the participants to investigate what this meant for individualized treatment.

Microbiological and Biochemical Analyses: To find possible infections linked to CAD, microbial cultures and polymerase chain reaction (PCR) methods were used. 16S rRNA sequencing was used to examine the makeup of the gut microbiome. To assess systemic metabolic and inflammatory conditions, standard biochemical tests were performed, such as lipid profiles and inflammatory markers (e.g., C-reactive protein).

Data Analysis: To investigate relationships between pharmaceutical, microbiological, clinical, and anatomical factors, quantitative data were examined using statistical software. Descriptive statistics, chi-square tests, and logistic regression analyses were used. To find independent predictors of CAD outcomes and account for relevant confounders, multivariate analyses were performed.

RESULTS

The average age of the 130 participants in the research was 53.8 years (± 9.45). Sixty percent of the participants were men (78 people), and forty percent were women (52 people). Sixty-three percent (82 people) of the cohort had hypertension, while forty-eight percent (62 people) had Type 2 Diabetes Mellitus. Of the participants, 35% (46 people) reported smoking, and 22% (29 people) were obese, meaning their BMI was higher than 30. Furthermore, 70% (91 people) of the participants had a family history of CAD. The significant prevalence of conventional cardiovascular risk factors in this group is highlighted by these demographic and clinical features, highlighting the significance of these variables in the context of CAD risk assessment. as displayed in Table 1.

Table 1: Demographic and Clinical Characteristics

Variable	Value
Sample Size	130
Mean Age (years)	53.8 ± 9.45
Gender (Male/Female)	78 (60%) / 52 (40%)
Hypertension (%)	82 (63%)
Type 2 Diabetes Mellitus (%)	62 (48%)
Smoking (%)	46 (35%)
Obesity (BMI >30) (%)	29 (22%)
Family History of CAD (%)	91 (70%)

The distribution of coronary artery disease (CAD) severity by gender is shown in Figure 1. In men, mild CAD was present in 32 (41%) of them, moderate CAD in 25 (32%) and severe CAD in 21 (27%) of them. On the other hand, 5 (10%) had severe CAD, 14 (27%) had moderate CAD, and 33 (63%) had mild CAD among females. This implies that compared to men, women often have lesser sickness. Gender did not affect CAD severity in this cohort, according to a chi-square test that found no statistically significant correlation between the two variables ($p = 0.983$). These results demonstrate the intricacy of CAD and imply that other variables could be more important in assessing the severity of the condition.



Figure 1: Gender and CAD Severity

The association between individuals' microbial presence and statin usage is seen in Table 2. Of the 56 statin users, 22 (28%) had microbiological presence and 34 (44%) did not. On the other hand, 57 (74%) of the 74 non-users exhibited no microbial presence, whereas 17 (22%) did. Despite these variations, there was no statistically significant correlation between the presence of microorganisms and the usage of statins, according to logistic regression analysis ($p = 0.664$). This implies that the presence of microbial infections in individuals with coronary artery disease is not much impacted by statin therapy. These results suggest that although statins are good at lowering inflammation, they might not have

much of an effect on infection-driven inflammation in CAD. It is necessary to look at additional variables that affect the microbial presence in CAD.

Table 2: Statin Use and Microbial Presence

Statin Use	Microbial Presence (%)	Microbial Absence (%)	Total
Yes	22 (28%)	34 (44%)	56
No	17 (22%)	57 (74%)	74

Eighty-three percent of individuals with moderate disease had normal coronary arteries, whereas seventeen percent had anomalous arteries. Of individuals with moderate severity, 62% had normal arteries and 38% had anomalous arteries. Of the patients with serious illness, 46% had normal arteries and 54% had anomalous arteries. These results imply that individuals with more severe coronary artery disease have a greater incidence of anomalous arteries, suggesting that anatomical differences may have a role in the severity and course of the ailment. As seen in figure 2.



Figure 2: Anatomical Variations and CAD Severity

There were rather many members of the research group with the following infections: Of the 27% of cases (35), 27% were Chlamydia pneumoniae; 80% of them had elevated C-reactive protein (CRP). Seventy percent of the tested persons had a high CRP; twenty percent had Helicobacter pylori. Not least of all, 12% (16 cases) of individuals had Porphyromonas gingivalis, and 88% of them had increased CRP. Strong links between these pathogens and high levels of inflammatory markers revealed by these findings support the evidence that they might be involved in the onset of coronary artery disease. Table 3 displays frequency of certain diseases observed.

Table 3: Pathogen Prevalence in CAD Patients

Pathogen	**Prevalence (%)**	**Elevated CRP (%)**	**Total**
Chlamydia pneumoniae	35 (27%)	28 (80%)	35
Helicobacter pylori	23 (18%)	16 (70%)	23
Porphyromonas gingivalis	16 (12%)	14 (88%)	16

When one considers medication therapy, microbiological data, anatomical anomalies, and demographic factors all together, one can better appreciate the complexity of CAD. Those with several risk factors, including structural defects and body microbes, had far less intensity of CAD. These findings emphasize the need of using an integrated approach for CAD management.

DISCUSSION

According to earlier studies, men as well as middle-aged and elderly persons are most prone to have coronary artery disease (CAD [11]). The subjects of the study meet this description. This group indicates how widespread diabetes mellitus and high blood pressure are, which emphasizes their significance as main CAD risk factors. When considering South Asian populations, where the increase in CAD arises from more persons having non-communicative disorders

like diabetes and high blood pressure [12], these findings particularly pique curiosity. This emphasizes how crucial it is to control these risk factors by means of focused preventative actions, hence reducing the local cardiovascular incidence. Research has indicated in other groups that men often have more severe types of CAD. This investigation did not, however, detect a statistically significant relationship between gender and CAD degree [13]. Many things could lead to this variation, including variations in genes, behavior, or health care availability. More research has to be done to ascertain whether women's higher risk of mild CAD results from different health practices or from delayed diagnosis. Given the complex ways that CAD severity and development might vary for men and women, more research could be required. This is particularly true considering how cultural elements and the local healthcare system could influence individuals' usage of medical treatment.

The researchers discovered that statin use had no appreciable correlation with microorganism presence. This aligns with our current knowledge: while statins help to lower inflammation, they might not be as effective on inflammation resulting from long-term infections [14]. Mostly influencing lipid levels, statins have proved to reduce cardiovascular events. Their anti-inflammatory properties might not be able to adequately address inflammation brought on by bacterial infections, though, which would aggravate atherosclerosis [15]. To eliminate the inflammation brought on by infections, CAD sufferers hence require more focused therapy including antibiotics. Combining statins with antimicrobial therapies may help to treat CAD more successfully, particularly in cases of bacterial infections [16]. The study revealed that those with coronary artery anomalies were more likely to have severe CAD, which supports the theory that anatomic variations can aggravate ischemia occurrences. One kind of anatomical issue that can slow down blood flow and hasten the course of an illness is aberrant coronary arteries [17]. This emphasizes how crucial it is to promptly identify these issues using cutting-edge imaging modalities as cardiac computed tomography angiography (CCTA) and intravascular ultrasonic (IVUS). Treatments must be tailored depending on the particular anatomy of every patient to yield the greatest outcomes for them. In areas with limited resources where these issues might not be immediately evident, this is particularly crucial. Understanding these variations and how they potentially influence the severity of CAD would enable doctors create more customized treatment approaches.

Increasing amounts of data point to microbial infections' involvement in CAD's development and spread. The findings of the study complement this corpus of knowledge. Higher degrees of inflammatory markers have been connected to organisms including Chlamydia pneumoniae. Long-term infections may thus induce inflammation, which could lead to atherosclerosis [19]. After reading this, it seems more likely that microbial infections are a main cause of CAD. The prevalence of these infections among members of this group could differ from that of individuals elsewhere. This can be the result of variations in the surroundings, the residents' quality of life, or their capacity to obtain medical attention [20]. More research is required to completely grasp these variations in the most often occurring kinds of bacteria found in various regions of the globe. These variations might reveal a lot about the part infections play in CAD and guide our design of more successful treatments.

This study reveals that CAD is complex; pharmacological, microbiological, structural, and socioeconomic elements all interact to influence patient performance and disease severity [21]. The outcomes of the study fit more general patterns in CAD research. They also inform us a lot, though, about regional trends that other studies might not have thoroughly addressed. For example, the particular patterns of microbiological infections and the higher prevalence of risk factors like diabetes and high blood pressure in this population highlight the need of considering local epidemiological characteristics while designing strategies to prevent and treat CAD. This study emphasizes the need of using a comprehensive approach to CAD considering genetic, social, microbiological, and anatomical elements to enhance patient care and outcomes.

Limitation and Future Suggestions: This study's cross-sectional design is one of its main shortcomings since it makes it more difficult to establish causal relationships between the investigated elements. The fact that the study was conducted just at one location limits the extent of data utilization. To corroborate these findings, future studies should concentrate on multicenter, longitudinal studies and investigate the long-term consequences of medication therapies including microbiology in CAD. Furthermore improving CAD treatment would be further research on the influences of gut microbiota and genetic elements in individualized therapeutic programs.

CONCLUSION

With an emphasis on how microbiological, anatomical, pharmacological, and demographic factors influence the growth and degree of the disease, it was underlined at the end of the study how complex and diverse CAD is. Although the statistics provide valuable fresh information on the frequency of CAD in our region, more study is needed to ensure these findings are accurate and investigate focused treatment methods, particularly with regard to microbiological origins and bespoke pharmacological approaches. Combining all these elements might result in improved CAD care and preventative strategies, which would eventually be beneficial for patients.

REFERENCES

1. Vilne, Baiba, and Heribert Schunkert. "Integrating genes affecting coronary artery disease in functional networks by multi-OMICs approach." Frontiers in cardiovascular medicine 5 (2018): 89.

2. Usova, EIena I., Asiiat S. Alieva, Alexey N. Yakovlev, Madina S. Alieva, Alexey A. Prokhorikhin, Alexandra O. Konradi, Evgeny V. Shlyakhto, Paolo Magni, Alberico L. Catapano, and Andrea Baragetti. "Integrative analysis of multi-omics and genetic approaches—a new level in atherosclerotic cardiovascular risk prediction." Biomolecules 11, no. 11 (2021): 1597.
3. Severino, Paolo, Andrea D'Amato, Mariateresa Pucci, Fabio Infusino, Francesco Adamo, Lucia Ilaria Birtolo, Lucrezia Netti et al. "Ischemic heart disease pathophysiology paradigms overview: from plaque activation to microvascular dysfunction." International journal of molecular sciences 21, no. 21 (2020): 8118.
4. Singh, Nirupma, Sneha Rai, Rakesh Bhatnagar, and Sonika Bhatnagar. "Network analysis of host-pathogen protein interactions in microbe induced cardiovascular diseases." In Silico Biology 14, no. 3-4 (2022): 115-133.
5. Sheng, Song, Qiao-Ning Yang, Hao-Ning Zhu, and Yong-Yue Xian. "Network pharmacology-based exploration of the mechanism of Guanxinning tablet for the treatment of stable coronary artery disease." World Journal of Traditional Chinese Medicine 7, no. 4 (2021): 456-466.
6. Doran, Stephen, Muhammad Arif, Simon Lam, Abdulahad Bayraktar, Hasan Turkez, Mathias Uhlen, Jan Boren, and Adil Mardinoglu. "Multi-omics approaches for revealing the complexity of cardiovascular disease." Briefings in bioinformatics 22, no. 5 (2021): bbab061.
7. Liang, Bo, Xiao-Xiao Zhang, and Ning Gu. "Virtual screening and network pharmacology-based synergistic mechanism identification of multiple components contained in Guanxin V against coronary artery disease." BMC Complementary Medicine and Therapies 20 (2020): 1-13.
8. Abdulsalam, Mustapha, Aisha Abba Hamisu, Aisha Musa Ahmad, Fatima Balarabe Wakili, Fatima Sulaiman Annu, and Maryam Murtala Garba. "Microbiome Dynamics and Strategic Management Strategies: Exploring Synergies between Integrative Medicine Modalities and Microbial Balance." Biological Sciences 4, no. 3 (2024): 725-735.
9. Corredor, Zuray, Andrés Suarez-Molina, Cristian Fong, Laura Cifuentes-C, and Sandra Guauque-Olarte. "Presence of periodontal pathogenic bacteria in blood of patients with coronary artery disease." Scientific reports 12, no. 1 (2022): 1241.
10. Fioranelli, Massimo, Anna G. Bottaccioli, Francesco Bottaccioli, Maria Bianchi, Miriam Rovesti, and Maria G. Roccia. "Stress and inflammation in coronary artery disease: a review psychoneuroendocrineimmunology-based." Frontiers in immunology 9 (2018): 2031.
11. Selvarajan, Ilakya, Anu Toropainen, Kristina M. Garske, Maykel López Rodríguez, Arthur Ko, Zong Miao, Dorota Kaminska et al. "Integrative analysis of liver-specific non-coding regulatory SNPs associated with the risk of coronary artery disease." The American Journal of Human Genetics 108, no. 3 (2021): 411-430.
12. Liu, Honghong, Xi Chen, Xiaomin Hu, Haitao Niu, Ran Tian, Hui Wang, Haiyu Pang et al. "Alterations in the gut microbiome and metabolism with coronary artery disease severity." Microbiome 7 (2019): 1-14.
13. Sun, Baoqing, Teng Ma, Yalin Li, Ni Yang, Bohai Li, Xinfu Zhou, Shuai Guo et al. "Bifidobacterium lactis Probio-M8 adjuvant treatment confers added benefits to patients with coronary artery disease via target modulation of the gut-heart/-brain axes." Msystems 7, no. 2 (2022): e00100-22.
14. Jin, Ling, Xiaoming Shi, Jing Yang, Yangyu Zhao, Lixiang Xue, Li Xu, and Jun Cai. "Gut microbes in cardiovascular diseases and their potential therapeutic applications." Protein & cell 12, no. 5 (2021): 346-359.
15. Vasquez, Elisardo C., Thiago MC Pereira, Veronica A. Peotta, Marcelo P. Baldo, and Manuel Campos-Toimil. "Probiotics as beneficial dietary supplements to prevent and treat cardiovascular diseases: uncovering their impact on oxidative stress." Oxidative medicine and cellular longevity 2019, no. 1 (2019): 3086270.
16. Tang, WH Wilson, Fredrik Bäckhed, Ulf Landmesser, and Stanley L. Hazen. "Intestinal microbiota in cardiovascular health and disease: JACC state-of-the-art review." Journal of the American College of Cardiology 73, no. 16 (2019): 2089-2105.
17. Wu, Haicui, and Jiachi Chiou. "Potential benefits of probiotics and prebiotics for coronary heart disease and stroke." Nutrients 13, no. 8 (2021): 2878.
18. Wu, Yeshun, Bin Zhu, Zijun Chen, Jiahao Duan, Ailin Luo, Ling Yang, and Chun Yang. "New insights into the comorbidity of coronary heart disease and depression." Current problems in cardiology 46, no. 3 (2021): 100413.
19. Leopold, Jane A., and Joseph Loscalzo. "Emerging role of precision medicine in cardiovascular disease." Circulation research 122, no. 9 (2018): 1302-1315.
20. Wu, Dong-Ning, Le Guan, Yi-Xin Jiang, Su-Hua Ma, Ya-Nan Sun, Hong-Tao Lei, Wei-Feng Yang, and Qing-Feng Wang. "Microbiome and metabonomics study of quercetin for the treatment of atherosclerosis." Cardiovascular Diagnosis and Therapy 9, no. 6 (2019): 545.
21. Zakir, Mehreen, Neha Ahuja, Marvi Alais Surksha, Reya Sachdev, Yash Kalariya, Muhammad Nasir, Maham Kashif et al. "Cardiovascular complications of diabetes: from microvascular to macrovascular pathways." Cureus 15, no. 9 (2023).